Trial
NCT01508000
Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Collaborators
Amgen; Roche Pharma AG
Condition
Colorectal Cancer Metastatic
Intervention
FOLFOX6
Why stopped
Low or poor accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-10-12